Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790066 | 0.84 | KDM4E (0.48) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL6707981 | 0.83 | ALDH1A1 (0.53) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL6789557 | 0.81 | DRD2 (0.42) | HRH3DRD2SLC6A4 | |
| SCHEMBL6789412 | 0.78 | SLC6A2 (0.43) | SLC6A4 | |
| SCHEMBL6791223 | 0.77 | SLC6A4 (0.49) | HRH3DRD2SLC6A4 | |
| SCHEMBL6707921 | 0.76 | ALDH1A1 (0.56) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL6784237 | 0.75 | DRD2 (0.43) | ALDH1A1DRD2SLC6A4 | |
| SCHEMBL10589925 | 0.68 | WDR5 (0.50) | KDM4EALDH1A1POLB | |
| SCHEMBL20537238 | 0.67 | HPGD (0.51) | KDM4EALDH1A1POLB | |
| SCHEMBL26208674 | 0.67 | HPGD (0.46) | POLBMAPK1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | KDM4E 1640/4885BRD4 664/4885ALDH1A1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.